


CURRENT SHORTAGES

- [Benzocaine-Menthol 20%-0.5% \(Dermoplast\) Topical Spray](#)
- [Calcium Gluconate Injection](#)
- [Ceftolozane / Tazobactam Injection](#)
- [Chlordiazepoxide capsules](#)
- [Chloroprocaine 3% injection](#)
- [Disopyramide CR Capsule](#)
- [Gentamicin 20mg/2mL PF Injection](#)
- [Hydroxocobalamin injection](#)
- [Immune Globulin, Intravenous \(IVIG\)](#)
- [Mesalamine 400mg Delayed Release Capsule](#)
- [Methohexital injection](#)
- [Methyldopa Tablet](#)
- [Mineral Oil, Sterile Topical](#)
- [Misoprostol Tablet](#)
- [Monsel's \(Ferric Subsulfate\) Solution](#)
- [Multivitamin Oral Liquid](#)
- [Multivitamin with Minerals](#)
- [PEG3350 Balanced Electrolyte Solution \(BES\) for Colonoscopy](#)
- [Physostigmine Injection](#)
- [Sincalide Injection \(Kinevac®\) Shortage](#)
- [Sucrose 24% Oral Solution 2mL Vial](#)

To: YNHHS Medical Staff, Pharmacy Staff, Nursing Staff
From: YNHHS Department of Pharmacy Services
Subject: **SBAR: Tocilizumab Injection Shortage**
Date: August 16, 2021

This communication applies to ALL sites within the Yale New Haven Health System

- S:** There is a critical nationwide shortage of tocilizumab which is used in the treatment of inpatients with severe COVID-19 infection.
- B:** The manufacturer of tocilizumab is unable to supply the market consistently due to increased demand given the recent rise in COVID-19 cases across the US.
- We have nearly exhausted our supply of tocilizumab at this point in time. It is not clear when we will receive additional supplies.
- A:** YNHHS's supply of intravenous tocilizumab has now reached a critically low level.
- R:** The alternative agent in lieu of tocilizumab for severe COVID-19 infection will be baricitinib. The Adult Inpatient YNHHS COVID-19 has been updated as follows:



- R:** For patients who have enteral access, baricitinib can be administered as follows:
- 1) Disperse baricitinib tablets in the amount of water indicated below and administer the solution to the patient.
 - 2) Then rinse the container with the amount of water below and then administer to the patient.

Administration Via:	Disperse Tablet With:	Rinse Container With:
Oral solution	10 ml water	10 ml water
Gastrostomy tube (G-tube)	20 ml water	20 ml water
Nasogastric (NG) tube Orogastric (OG) tube Nasojejunal (NJ) tube Jejunal (J) tube	30 ml water	30 ml water

The above tocilizumab restriction does not apply its inpatient for the management of cytokine release syndrome in CAR-T patients.

References:

1. Anonymous. Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Baricitinib. July 2021. Available at: <http://pi.lilly.com/eua/baricitinib-eua-factsheet-hcp.pdf>
2. Marconi VC, Ramanan VA, de Bono S et al. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19. medRxiv preprint May 3, 2021. Available at: <https://doi.org/10.1101/2021.04.30.21255934>.
3. Kalil AC, Patterson TF, Mehta AK et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. NEJM. 2021. 2021 Mar 4;384(9):795-807.